Precirix

Precirix is a Belgium-based biotechnology company that focuses on developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company's lead product, CAM-H2, is currently undergoing a Phase I/II clinical trial to target HER2-positive tumors, with plans to expand its oncology pipeline. What sets Precirix apart is its technology platform, enabling a theranostic approach by using the same molecule for patient selection (imaging) and therapy. With its dedication to improving the lives of cancer patients, Precirix has garnered substantial support, with its latest funding being an €80.00M Series B investment on 16 March 2022. The notable investors in this round include Novo Holdings, Pontifax, Forbion, HealthCap, GIMV, BioMed Partners, Jeito Capital, V-Bio Ventures, and Inkef. As a clinical-stage biotechnology company, Precirix has positioned itself at the forefront of precision radiopharmaceuticals, displaying promising potential for growth and impact in the healthcare industry.